CF-404 is a therapeutic cocktail composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. Animal studies show that CF-404 protects animals from a broad range of influenza viruses. These highly potent antibodies are effective at low doses and have the potential to be active when administered beyond the treatment window limit for current influenza therapies, which are indicated to be used within 48 hours of symptom onset. The goal of the CF-404 program is to create a universal influenza therapy covering all human seasonal strains by targeting highly conserved sites on a diverse family of influenza viruses.


CF-404 is designed to provide coverage of all human seasonal influenza strains in a single treatment. While the flu virus changes every year, necessitating new vaccines each year, CF-404 is targeted to a conserved region of the virus that does not change. By covering a wide range of different strains, patients can be treated faster without the need for a diagnostic to determine if a patient is a candidate for therapy.

CF-404 also is expected to have an extended “treatment window”, which is the time after initial symptoms where a treatment is effective. A major shortcoming of current treatment options is that they are indicated for use within 48 hours of symptom onset, which means patients who require treatment after 48 hours have limited options. In animal studies, CF-404 has been shown to be effective when administered more than 48 hours after the onset of symptoms.

Market Need

Every year a significant number of people develop a serious influenza infection despite the availability of seasonal flu vaccine. According to the CDC, on average over 200,000 people are hospitalized and up to 49,000 people die each year in the U.S. from seasonal flu-related illness. This is particularly problematic in individuals with less robust immune systems such as infants, elderly individuals, and patients who are otherwise immunocompromised such as those with HIV/AIDS, receiving cancer chemotherapy, or using transplant rejection therapies. ContraFect’s antibody cocktail is designed to treat patients who become seriously ill with influenza.


Annual hospitilizations due to influenza, in the U.S.

Up To49,000

Annual deaths due to influenza, in the U.S.

Influenza Program

Our influenza program has attracted government attention:

  • U.S. government: $3.3 Million SBIR grant
  • Chinese government: Collaborations with the Centers for Disease Control and Prevention

Clinical Summary

CF-404 is currently in IND-enabling preclinical studies.


Lysin Candidate: CF-301

CF-301, is a lysin for the treatment of Staph aureus bacteremia.

View CF-301 »


Our lysin and monoclonal antibody products represent new, potentially game-changing approaches to treating infections, including those caused by drug resistant pathogens.

Learn More »